European Prevention of Alzheimer's Dementia (EPAD)

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">European Prevention of Alzheimer's Dementia (EPAD)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>EPAD Consortium Logo</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Pan-European (coordinated from Edinburgh, UK)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Consortium</td>
</tr>
<tr>
<td class="label">Launched</td>
<td>2015</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Completed (2022)</td>
</tr>
<tr>
<td class="label">Coordinator</td>
<td>University of Edinburgh</td>
</tr>
<tr>
<td class="label">Funding</td>
<td>€64 million (EU Horizon 2020)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.ep-ad.org/" target="_blank">ep-ad.org</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers) Prevention, Clinical Trials, Biomarkers, Early Detection</td>
</tr>
</table>

European Prevention of Alzheimer's Dementia (EPAD)

Overview

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">European Prevention of Alzheimer's Dementia (EPAD)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>EPAD Consortium Logo</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Pan-European (coordinated from Edinburgh, UK)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Consortium</td>
</tr>
<tr>
<td class="label">Launched</td>
<td>2015</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Completed (2022)</td>
</tr>
<tr>
<td class="label">Coordinator</td>
<td>University of Edinburgh</td>
</tr>
<tr>
<td class="label">Funding</td>
<td>€64 million (EU Horizon 2020)</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.ep-ad.org/" target="_blank">ep-ad.org</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers) Prevention, Clinical Trials, Biomarkers, Early Detection</td>
</tr>
</table>

European Prevention of Alzheimer's Dementia (EPAD)

Overview

The European Prevention of Alzheimer's Dementia (EPAD) was a ambitious pan-European research consortium dedicated to preventing Alzheimer's disease dementia through innovative clinical trial designs and comprehensive biomarker research. Launched in 2015 with €64 million in funding from the European Union's Horizon 2020 research program, EPAD represented one of the largest coordinated efforts to understand and prevent Alzheimer's disease in Europe [@european].

EPAD was designed to address a critical bottleneck in Alzheimer's disease research: the difficulty of conducting clinical trials for prevention therapies. By creating a unified registry of research participants and standardizing biomarker assessment across Europe, EPAD aimed to accelerate the development of effective treatments that could be administered years before symptoms appear [@ritchie2020].

The consortium was coordinated by the University of Edinburgh and brought together over 40 academic and industry partners across more than 20 European countries. EPAD built upon the foundation established by the Dominantly Inherited Alzheimer Network (DIAN) in the United States, extending the prevention trial model to sporadic Alzheimer's disease, which accounts for over 95% of cases [@dominantly].

Mission and Objectives

EPAD's primary mission was to develop and validate markers of Alzheimer's disease progression to enable effective prevention trials in individuals at risk of developing dementia. The consortium pursued several key objectives:

Research Infrastructure

EPAD Longitudinal Cohort Study

The cornerstone of EPAD was its Longitudinal Cohort Study, which enrolled approximately 2,000 participants across over 100 sites in Europe. Participants were selected to represent different stages of Alzheimer's disease pathology, from cognitively normal individuals to those with mild cognitive impairment [@solomon2018].

The cohort was designed with the following characteristics:

• Age range: 50-85 years
• Cognitive status: Including cognitively normal, subjective cognitive decline, mild cognitive impairment, and early-stage Alzheimer's disease
• biomarker profile: Participants underwent comprehensive biomarker assessment including:
• Amyloid PET imaging ([PIB](/mechanisms/amyloid-cascade), flutemetamol)
• Tau PET imaging ([Flortaucipir](/mechanisms/tau-pathology))
• Cerebrospinal fluid analysis ([Aβ42/40 ratio](/mechanisms/cerebrospinal-fluid), [tau](/mechanisms/tau-pathology), [p-tau](/mechanisms/tau-pathology))
• Structural MRI
• Cognitive assessments

EPAD Registry

The EPAD Registry was designed as a pan-European database of individuals interested in participating in Alzheimer's prevention research. Unlike traditional patient registries, EPAD proactively recruited cognitively healthy individuals at various levels of Alzheimer's disease risk, creating a pipeline for clinical trial enrollment [@epad].

The registry utilized a staged risk enrichment approach:

• Stage 1: Community-based recruitment of cognitively normal individuals
• Stage 2: Biomarker screening to identify amyloid-positive individuals
• Stage 3: Randomization into clinical trials based on biomarker status

Standardized Protocols

EPAD established standardized protocols for:

• Neuropsychological assessment using the EPAD Neuropsychological Battery (EPAD-NB)
• MRI imaging following harmonized protocols
• PET imaging for amyloid and tau detection
• CSF collection using standardized operating procedures
• Data management through a centralized data platform [@frisoni2019]

Key Studies and Trials

POINER Trial

The POINER (Proof of Concept Immunotherapy in Alzheimer's Disease) study was EPAD's first clinical trial, evaluating the effects of gosuranemab, an anti-tau monoclonal antibody, in individuals with preclinical Alzheimer's disease. This study demonstrated the feasibility of recruiting and retaining participants in prevention trials using the EPAD infrastructure [@poiner].

AMARANTH Trial

The AMARANTH study evaluated elenbecestat, a BACE inhibitor developed by Eisai, in individuals with preclinical Alzheimer's disease. Although the trial was discontinued due to safety concerns unrelated to efficacy, it provided valuable data on BACE inhibition in early disease stages [@amaranth].

Other EPAD-Funded Studies

EPAD supported multiple secondary prevention trials, including studies targeting:

• Amyloid clearance ([Anti-amyloid immunotherapies](/therapeutics/amyloid-immunotherapy))
• Neuroinflammation ([Anti-inflammatory approaches](/mechanisms/neuroinflammation))
• Synaptic function ([Synaptic protection](/mechanisms/synaptic-loss))
• Metabolic function ([Brain metabolism](/mechanisms/cerebral-metabolism))

Biomarker Research

EPAD made significant contributions to Alzheimer's disease biomarker research:

Amyloid and Tau Biomarkers

The consortium validated the use of CSF biomarkers for identifying individuals with preclinical Alzheimer's disease, confirming that:

• Low CSF Aβ42/40 ratio predicts amyloid PET positivity
• Elevated CSF total tau and p-tau indicate ongoing neuronal injury
• Combination of biomarkers improves predictive accuracy [@blennow2020]

Fluid Biomarkers

EPAD researchers explored novel fluid biomarkers including:

• Neurofilament light chain (NfL) as a marker of neuronal injury
• GFAP (glial fibrillary acidic protein) as a marker of astrocyte activation
• YKL-40 as a marker of neuroinflammation [@teunissen2022]

Digital Biomarkers

The consortium also investigated digital cognitive assessments and wearable device data as potential biomarkers for early cognitive decline [@koychev2021].

Participating Institutions

EPAD brought together leading European research institutions, including:

Academic Partners

• University of Edinburgh (UK) — Coordinating center
• Karolinska Institutet (Sweden)
• University of Cambridge (UK)
• University of Oxford (UK)
• University of Amsterdam (Netherlands)
• University of Basel (Switzerland)
• Inserm (France)
• Charité Berlin (Germany)
• IRCCS Fatebenefratelli (Italy)
• Universidad de Navarra (Spain)

Industry Partners

• Eli Lilly and Company
• Eisai Co., Ltd.
• Biogen
• Janssen Pharmaceuticals
• Roche
• Merck KGaA
• GlaxoSmithKline

Impact and Legacy

EPAD has made lasting contributions to Alzheimer's disease research:

Methodological Innovations

• Adaptive platform trials: EPAD pioneered the use of adaptive trial designs that allow for more efficient testing of multiple therapies
• Registry-based recruitment: The consortium demonstrated the feasibility of large-scale biomarker screening to identify suitable trial participants
• Data sharing: EPAD established models for data sharing that have been adopted by other consortia [@brooker2023]

Scientific Publications

EPAD produced over 100 peer-reviewed publications, covering topics from biomarker validation to clinical trial methodology. Key publications include:

• Publications on CSF biomarker standardization
• Methodological papers on adaptive trial designs
• Baseline characteristics of the EPAD cohort
• Results from multiple clinical trials [@epada]

Transition to REAL

Following the completion of EPAD in 2022, the consortium's infrastructure transitioned to the REAlity of Life (REAL) initiative, which continues to follow the EPAD cohort longitudinally and serves as a platform for new prevention trials [@real].

Relationship to Other Initiatives

DIAN

EPAD was closely related to the US Dominantly Inherited Alzheimer Network (DIAN), which studies individuals with genetic forms of Alzheimer's disease. While DIAN focuses on autosomal dominant AD (caused by mutations in [APP](/genes/APP), [PSEN1](/genes/PSEN1), or [PSEN2](/genes/PSEN2)), EPAD focused on sporadic AD, which is far more common [@dominantly].

A4 Study

The US Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study was another key prevention trial that paralleled EPAD's efforts. EPAD and A4 shared methodological approaches and collaborated on biomarker standardization [@sperling2014].

Global Alzheimer's Association

EPAD was a founding member of the Global Alzheimer's Association Interactive Network (GAAIN), which aims to share data across international Alzheimer's research consortia [@global].

Future Directions

The learnings from EPAD continue to inform current Alzheimer's prevention initiatives:

• Lecanemab and donanemab approvals have validated the amyloid-targeting approach in early-stage disease
• Combination therapies targeting multiple pathological features are now being tested
• Precision prevention approaches using genetic and biomarker risk profiles are under development
• Digital health integration for continuous monitoring is becoming standard [@cummings2023]

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Biomarkers in AD](/mechanisms/biomarkers-ad)
• [Clinical Trials in Alzheimer's](/diseases/alzheimers#clinical-trials)
• [Dominantly Inherited Alzheimer Network (DIAN)](/research-consortia/dian)
• [Preclinical Alzheimer's Disease](/diseases/alzheimers#preclinical-stage)

External Links

• [EPAD Website](https://www.ep-ad.org/) (archived)
• [University of Edinburgh EPAD Page](https://www.ed.ac.uk/)
• [EPAD Publications](https://pubmed.ncbi.nlm.nih.gov/?term=EPAD+consortium)
• [GAAIN](https://www.gaain.org/)

References